Chemotherapy for advanced gastric cancer: Ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study)

International Journal of Clinical Oncology

Volumn 13, Issue 3, 2008, Pages 201-205

  Fujii, Masashi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Docetaxel; Gastric cancer; Phase III study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOCETAXEL;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SAFETY; FOLLOW UP; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; HUMANS; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TEGAFUR;

EID: 45749138007     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0775-1     Document Type: Review

References (22)

1. Tsukuma H (ed) (2002) Progress Report of the Research Group for Population-based Cancer Registration in Japan. Cancer Statistics: 2002 Shinohara Shuppan, Tokyo
2. Kitagawa T, Tsukuma H, Ajiki K, et al. (1999) Prediction of cancer incidence in Japan. In: Tominaga S, et al. (eds) Cancer Statistics: 1999. Shinohara Shuppan, Tokyo
3. Comis S (1974) Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rep 1:221
4. Cocconi G, DeLisi V, DiBlasio B (1982) Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66:1263
5. The Gastrointestinal Tumor Study Group. (1979) Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1871
6. Moertel CG, Lavin PT (1979) Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1863
7. Preusser P, Achterrath W, Wilke H, et al. (1988) Chemotherapy of gastric cancer [Review]. Cancer Treat Rep 15:257
8. Murad AM, Santiago FF, Petroianu A, et al. (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (Phila) 72:37-41
9. Pyrhonen S, Kuitunen T, Nyandoto P, et al. (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
10. Waters JS, Norman A, Cunningham D, et al. (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269-272
11. Ohtsu A, Shimada Y, Shirao K, et al. (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59
12. Sakata Y, Ohtsu A, Horikoshi N, et al. (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer subjects. Eur J Cancer 34:1715-1720
13. Sulkes A, Smyth J, Sessa C, et al. (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70:380-383
14. Einzig AI, Neuberg D, Remick SC, et al. (1996) Phase II trial of docetaxel (Taxotere) in subjects with adenocarcinomas of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293. Med Oncol 13:87-93
15. Taguchi T, Sakata Y, Kanamaru R, et al. (1998) Late phase II clinical study of RP56976 (docetaxel) in subjects with advance/recurrent gastric carcinoma: a Japanese Cooperative Study Group Trial (Group A). Jpn J Cancer Chemother 25:1915-1924
16. Roth AD, Maibach R, Falk S, et al. (2004) Docetaxel-cisplatin-5-FU (TCF) versus docetaxel-displatin (TC) versus epirubicincisplatin-5-FU (ECF) as systemic treatment for advanced gastric carcinoma (ACG): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 23:317 (abstract 4020)
17. Moiseyenko VM, Ajani JA, Tjulandin A, et al. (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23:308s (abstract 4002)
18. Yoshida K, Ninomiya M, Takakura N, et al. (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3042-3047
19. Yamaguchi K, Shimamura T, Hyodo I, et al. (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803-1808
20. Verweij J (1999) Rational design of new tumor-activated cytotoxic agents. Oncology. 57:9
21. Kurosumi M, Tabei T, Suemasu K, et al. (2000) Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neo-adjuvant chemotherapy in advanced breast cancer subjects. Oncol Rep 7:945
22. Yoshida K, Nishiyama M, Toge T, et al. (2003) Combination phase I/II study of S-1 and docetaxel with advanced or recurrent gastric cancer. Proc Am Soc Clin Oncol 22:322 (abstract 1292)